-+ 0.00%
-+ 0.00%
-+ 0.00%

Keymed Biosciences Announces 2026 H1 Results and Business Updates

Barchart·08/21/2026 04:13:00
Listen to the news

CHENGDU, China, Aug. 21, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026, with total revenue of RMB617 million. Core product Kangyueda generated sales of RMB393 million, up 132% YoY, supported by a nearly 500‑member commercial team covering 1,600+ hospitals. Collaboration revenue reached RMB224 million, mainly from AstraZeneca milestones. Profit for the period was RMB122 million, turning from loss to profit, while cash reserves stood at RMB3.24 billion.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.